Updated:
Vensana Capital
Vensana Capital is a Minneapolis medtech venture firm led by Justin Klein and Kirk Nielsen, with $425M raised across two dedicated funds.
Vensana Capital
Vensana Capital is an SEC-registered investment adviser based in Edina, MN, registered since 2019. It advises on investment strategies. The firm is headquartered in Edina.
General information
Firm type
Private Equity
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Edina
Corporate office
Minneapolis, MN, United States
Principals
Justin Klein
Managing Partner
Kirk Nielsen
Managing Partner
Sector focus
Frequently asked questions
Who runs investment decisions at Vensana Capital?
Managing Partners Justin Klein and Kirk Nielsen jointly lead the investment committee. Both have deep operating and investing backgrounds in medical technology. All investment decisions are made internally by the partnership.
What differentiates Vensana's medtech focus from generalist healthcare funds?
Vensana restricts its mandate to regulated medical devices, diagnostics, and data-enabled therapeutic technologies — it does not invest in biotech, healthcare services, or digital health platforms that lack a physical medical device component. This specialization gives the firm's team focused clinical and regulatory expertise that generalist funds rarely develop.
Which investment stages does Vensana Capital target?
The firm invests from early-stage venture rounds through late-stage growth equity, covering pre-commercial, clinical-trial-stage, and revenue-stage companies. This broad stage mandate allows Vensana to support portfolio companies across their entire development lifecycle.
Does Vensana Capital participate in fund commitments or only direct deals?
Vensana deploys capital primarily through direct equity investments and co-investments. There is no public indication that the firm allocates to third-party funds as a limited partner.
Which sectors does Vensana Capital explicitly avoid?
The firm does not invest in traditional biotechnology, pharmaceutical development, or pure healthcare services. Its mandate specifically excludes therapeutic areas that do not involve a regulated medical device or diagnostic platform.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: